Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
PharmaBlock Sciences (Nanjing), Inc. (300725.SZ)
Nanjing, CN
PharmaBlock Sciences (Nanjing), Inc. delivers a comprehensive suite of chemical products and specialized services, supporting the pharmaceutical industry across the full spectrum of its operations – from initial research and development phases to large-scale commercial production. The company's primary offerings encompass: A vast inventory of chemical building blocks, available for supply at every stage of drug creation, from early discovery through to advanced development and commercial manufacturing. The creation of diverse chemical libraries, derived from their building blocks, specifically designed to accelerate drug discovery processes. Contract development and manufacturing (CDMO) services for essential pharmaceutical components, including raw starting materials (RSMs), chemical intermediates, active pharmaceutical ingredients (APIs), and finished drug products, catering to both clinical development programs and market demands. Established in 2006, PharmaBlock Sciences maintains its corporate headquarters in Nanjing, People's Republic of China.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -2.62% | -5.29% | -11.44% | -12.15% | -7.55% | -8.48% | +4.35% | -32.97% | -75.76% | +448.83% | +448.83% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+16.9% ★ Q1'26: +11.7% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%-20.0% Q1'26: +16.7% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+24.1% ★ Q1'26: -5.9% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+12.3% Q1'26: +9.7% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+4.4% Q1'26: +4.0% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+4.6% Q1'26: +17.2% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×0.48× ★ Q1'26: 0.90× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
478.25M
est: 477.00M (+0.3%)
|
662.23M
est: 644.60M (+2.7%)
|
1.02B
est: 991.08M (+3.1%)
|
1.20B
est: 1.24B (-3.1%)
|
1.62B
est.
|
1.73B
est: 1.63B (+6.1%)
|
1.59B
est: 1.63B (-1.9%)
|
1.69B
est: 1.57B (+7.6%)
|
1.97B
est: 2.03B (-2.7%)
|
2.42B
2.42B – 2.42B
+19.5% YoY
|
2.85B
2.85B – 2.85B
+17.5% YoY
|
| EBITDA |
172.31M
est: 110.36M (+56.1%)
|
197.33M
est: 149.14M (+32.3%)
|
229.69M
est: 229.30M (+0.2%)
|
571.67M
est: 286.96M (+99.2%)
|
373.66M
est.
|
403.87M
est: 471.44M (-14.3%)
|
456.15M
est: 471.44M (-3.2%)
|
439.94M
est: 455.20M (-3.4%)
|
381.61M
est: 588.28M (-35.1%)
|
702.81M
702.81M – 702.81M
+19.5% YoY
|
825.45M
825.45M – 825.45M
+17.5% YoY
|
| EBIT |
155.41M
est: 85.10M (+82.6%)
|
176.22M
est: 115.00M (+53.2%)
|
205.21M
est: 176.82M (+16.1%)
|
518.46M
est: 221.28M (+134.3%)
|
288.13M
est.
|
289.57M
est: 370.09M (-21.8%)
|
369.91M
est: 370.09M (0.0%)
|
311.17M
est: 357.34M (-12.9%)
|
241.83M
est: 461.81M (-47.6%)
|
551.72M
551.72M – 551.72M
+19.5% YoY
|
647.99M
647.99M – 647.99M
+17.5% YoY
|
| Net Income |
133.36M
est: 132.27M (+0.8%)
|
152.07M
est: 161.20M (-5.7%)
|
184.21M
est: 203.88M (-9.6%)
|
486.56M
est: 493.82M (-1.5%)
|
370.22M
est.
|
197.36M
est: 191.95M (+2.8%)
|
314.22M
est: 191.95M (+63.7%)
|
219.54M
est: 206.70M (+6.2%)
|
183.74M
est: 158.68M (+15.8%)
|
225.49M
225.49M – 225.49M
+42.1% YoY
|
327.80M
327.80M – 327.80M
+45.4% YoY
|
| SGA |
76.66M
est: 69.78M (+9.9%)
|
94.84M
est: 94.30M (+0.6%)
|
149.81M
est: 144.99M (+3.3%)
|
172.31M
est: 181.45M (-5.0%)
|
236.27M
est.
|
252.14M
est: 200.91M (+25.5%)
|
246.65M
est: 200.91M (+22.8%)
|
237.58M
est: 193.99M (+22.5%)
|
64.91M
est: 250.70M (-74.1%)
|
299.50M
299.50M – 299.50M
+19.5% YoY
|
351.77M
351.77M – 351.77M
+17.5% YoY
|
| EPS |
0.72
est: 0.66 (+8.6%)
|
0.82
est: 0.81 (+1.5%)
|
0.99
est: 1.02 (-3.1%)
|
2.46
est: 2.47 (-0.6%)
|
1.86
est.
|
0.99
est: 0.92 (+7.7%)
|
1.58
est: 0.92 (+71.9%)
|
1.10
est: 0.99 (+11.1%)
|
0.88
est: 0.76 (+15.8%)
|
1.08
1.08 – 1.08
+42.1% YoY
|
1.57
1.57 – 1.57
+45.4% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-28 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-27 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-26 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-25 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-22 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-21 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-20 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-19 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-18 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-15 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-14 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-13 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-12 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-11 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-08 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-07 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-06 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-30 | B+ | 3/5 | 4/5 | 2/5 | 4/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-29 | B+ | 3/5 | 4/5 | 2/5 | 4/5 | 3/5 | 2/5 | 4/5 |
| 2026-04-28 | A- | 4/5 | 5/5 | 2/5 | 4/5 | 3/5 | 2/5 | 4/5 |
| 2026-04-27 | B+ | 3/5 | 5/5 | 2/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-24 | B+ | 3/5 | 5/5 | 2/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-23 | B- | 2/5 | 1/5 | 2/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-22 | B- | 2/5 | 1/5 | 2/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-21 | B- | 3/5 | 1/5 | 2/5 | 5/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-20 | B- | 3/5 | 1/5 | 2/5 | 5/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-17 | B- | 3/5 | 1/5 | 2/5 | 5/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-16 | B- | 3/5 | 1/5 | 2/5 | 5/5 | 2/5 | 1/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | State Street SPDR S&P Emerging Markets Small Cap ETF EWX | 0.01% | 103.5K | 0.65% |
| 2 | Dimensional - Emerging Markets Value ETF DFEV | 0.00% | 69.8K | 0.46% |
| 3 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 157.4K | 0.39% |
| 4 | Dimensional - Emerging Core Equity Market ETF DFAE | 0.00% | 78.8K | 0.29% |
| 5 | Vanguard FTSE Emerging Markets All Cap Index ETF VEE.TO | 0.00% | 24.5K | 0.26% |
| 6 | Vanguard FTSE Emerging Markets Shares ETF VGE.AX | 0.00% | 10.9K | 0.48% |
| 7 | Vanguard FTSE Emerging Markets ETF VWO | 0.00% | 1.21M | 0.06% |
| 8 | Dimensional World ex U.S. Core Equity 2 ETF DFAX | 0.00% | 77.6K | 0.28% |
| 9 | Vanguard Total International Stock ETF VXUS | 0.00% | 1.18M | 0.05% |
| 10 | Vanguard ESG International Stock ETF VSGX | 0.00% | 9.2K | 0.10% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| David Chen | Executive Vice President, Chief Operation Officer & Head of CDMO | — | — |
| Dezhi Sha | Sr. VP of Process Technology & Manufacturing | — | — |
| Jing Li | Sr. VP of Process Chemistry & President of PharmaBlock (USA), Inc. | — | — |
| Minmin Yang | Co-Founder, Chairman & Chief Executive Officer | — | — |
| Shanbao Yu | Secretary of the Board | — | male |
| Shijie Zhang | Chief Technology Officer | — | — |
| Shuhai Zhao | Co-founder & Chief Scientific Officer | — | male |
| Zhiho Ng Chen | Executive Vice President | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 300725.SZ
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
